Sublocade

Product manufactured by Indivior Inc.

Application Nr Approved Date Route Status External Links
NDA209819 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Sublocade Is Indicated For The Treatment Of Moderate To Severe Opioid Use Disorder In Patients Who Have Initiated Treatment With A Transmucosal Buprenorphine-Containing Product, Followed By Dose Adjustment For A Minimum Of 7 Days. Sublocade Should Be Used As Part Of A Complete Treatment Plan That Includes Counseling And Psychosocial Support. Sublocade Contains Buprenorphine, A Partial Opioid Agonist, And Is Indicated For The Treatment Of Moderate To Severe Opioid Use Disorder In Patients Who Have Initiated Treatment With A Transmucosal Buprenorphine-Containing Product, Followed By Dose Adjustment For A Minimum Of 7 Days. ( 1 ) Sublocade Should Be Used As Part Of A Complete Treatment Program That Includes Counseling And Psychosocial Support. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Buprenorphine BUPRENORPHINE ZINC100373348

Comments